Eculizumab and ravulizumab — treatments for atypical haemolytic uremic syndrome (aHUS), available in the U.S. as Soliris and biosimilars,…
Articles by Andrea Lobo
A 21-year-old man with atypical hemolytic uremic syndrome (aHUS) associated with Castleman disease improved after receiving treatment with iptacopan…
The case of a 29-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (aHUS) along with uncommon lung complications after…
People with atypical hemolytic uremic syndrome (aHUS) who completed self-assessments for a study scored lower on measures of physical…
A 26-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) successfully recovered following treatment with Soliris (eculizumab), according to a case…
A 29-year-old woman in the U.S. showed signs of atypical hemolytic uremic syndrome (aHUS) and a C2 gene mutation,…
Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with…
Atypical hemolytic uremic syndrome (aHUS) may be triggered by acute inflammation of the pancreas, or pancreatitis, a team of…
More than half of people with atypical hemolytic uremic syndrome (aHUS) in India have self-reactive antibodies targeting complement factor…
Plasma exchange therapy successfully managed atypical hemolytic uremic syndrome (aHUS) triggered by pancreas inflammation in a 72-year-old man, according…